Risperidone for children and adolescents with autism spectrum disorder: a systematic review

Narong Maneeton,1 Benchalak Maneeton,1 Suwannee Putthisri,2 Pakapan Woottiluk,3 Assawin Narkpongphun,1 Manit Srisurapanont1 1Department of Psychiatry, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; 2Department of Psychiatry, Faculty of Medicine, Ramathibodi Hospital, Mahidol Univ...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Maneeton N, Maneeton B, Putthisri S, Woottiluk P, Narkpongphun A, Srisurapanont M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	Risperidone Autism Spectrum Disorder Efficacy Acceptability Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/0f18bdfe980b4a8395765491e9c5d162
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0f18bdfe980b4a8395765491e9c5d162
record_format	dspace
spelling	oai:doaj.org-article:0f18bdfe980b4a8395765491e9c5d1622021-12-02T04:23:50ZRisperidone for children and adolescents with autism spectrum disorder: a systematic review1178-2021https://doaj.org/article/0f18bdfe980b4a8395765491e9c5d1622018-07-01T00:00:00Zhttps://www.dovepress.com/risperidone-for-children-and-adolescents-with-autism-spectrum-disorder-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Narong Maneeton,1 Benchalak Maneeton,1 Suwannee Putthisri,2 Pakapan Woottiluk,3 Assawin Narkpongphun,1 Manit Srisurapanont1 1Department of Psychiatry, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; 2Department of Psychiatry, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; 3Psychiatric Nursing Division, Faculty of Nursing, Chiang Mai University, Chiang Mai, Thailand Background: Various clinical trials suggested that risperidone was beneficial in the treatment of autism spectrum disorder (ASD) in children and adolescents. Objective: The aim of this systematic review was to determine the efficacy, acceptability and tolerability of risperidone in the treatment of children and adolescents with ASD. Data sources: The databases of Scopus, PubMed, CINAHL and Cochrane Controlled Trials Register were searched in February 2017. Study eligibility criteria, participants and interventions: Eligible RCTs of risperidone in the treatment of child and adolescent patients with ASD. Languages were not restricted. Study appraisal and synthesis methods: The full-text versions of relevant studies were thoroughly assessed and extracted. The primary efficacy of outcome was the pooled response rate and the pooled mean changed scores of the standardized rating scales for ASD. Results: A total of 372 randomized subjects from seven RCTs were included in this review. In acute treatment, the pooled mean change score of the Aberrant Behavior Checklist for irritability subscale (ABC-I) and response rate for the risperidone-treated group had a greater significance than that of the placebo-treated group. In the long-term treatment, the pooled mean change score of the CARS in the risperidone-treated group was significantly greater than that in the placebo-treated group. According to the discontinuation phase, the overall pooled relapse rate of the risperidone-treated group was significantly less than that of the placebo-treated group. The rates of pooled overall discontinuation and discontinuation due to adverse events rates were not different between the two groups in acute and long-term treatments. Limitations: A small study was included in the current review. Conclusion: In relation to the current systematic review, risperidone is efficacious in the treatment of symptoms in children and adolescents with ASD. Although its acceptability is comparable to placebo, treatment with risperidone is well tolerated in children and adolescents with ASD. Keywords: Aberrant Behavior Checklist, ABC, Childhood Autism Rating Scale, CARS, efficacy, acceptability, tolerabilityManeeton NManeeton BPutthisri SWoottiluk PNarkpongphun ASrisurapanont MDove Medical PressarticleRisperidoneAutism Spectrum DisorderEfficacyAcceptabilityRisperidoneNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 14, Pp 1811-1820 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Risperidone Autism Spectrum Disorder Efficacy Acceptability Risperidone Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Risperidone Autism Spectrum Disorder Efficacy Acceptability Risperidone Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Maneeton N Maneeton B Putthisri S Woottiluk P Narkpongphun A Srisurapanont M Risperidone for children and adolescents with autism spectrum disorder: a systematic review
description	Narong Maneeton,1 Benchalak Maneeton,1 Suwannee Putthisri,2 Pakapan Woottiluk,3 Assawin Narkpongphun,1 Manit Srisurapanont1 1Department of Psychiatry, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; 2Department of Psychiatry, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; 3Psychiatric Nursing Division, Faculty of Nursing, Chiang Mai University, Chiang Mai, Thailand Background: Various clinical trials suggested that risperidone was beneficial in the treatment of autism spectrum disorder (ASD) in children and adolescents. Objective: The aim of this systematic review was to determine the efficacy, acceptability and tolerability of risperidone in the treatment of children and adolescents with ASD. Data sources: The databases of Scopus, PubMed, CINAHL and Cochrane Controlled Trials Register were searched in February 2017. Study eligibility criteria, participants and interventions: Eligible RCTs of risperidone in the treatment of child and adolescent patients with ASD. Languages were not restricted. Study appraisal and synthesis methods: The full-text versions of relevant studies were thoroughly assessed and extracted. The primary efficacy of outcome was the pooled response rate and the pooled mean changed scores of the standardized rating scales for ASD. Results: A total of 372 randomized subjects from seven RCTs were included in this review. In acute treatment, the pooled mean change score of the Aberrant Behavior Checklist for irritability subscale (ABC-I) and response rate for the risperidone-treated group had a greater significance than that of the placebo-treated group. In the long-term treatment, the pooled mean change score of the CARS in the risperidone-treated group was significantly greater than that in the placebo-treated group. According to the discontinuation phase, the overall pooled relapse rate of the risperidone-treated group was significantly less than that of the placebo-treated group. The rates of pooled overall discontinuation and discontinuation due to adverse events rates were not different between the two groups in acute and long-term treatments. Limitations: A small study was included in the current review. Conclusion: In relation to the current systematic review, risperidone is efficacious in the treatment of symptoms in children and adolescents with ASD. Although its acceptability is comparable to placebo, treatment with risperidone is well tolerated in children and adolescents with ASD. Keywords: Aberrant Behavior Checklist, ABC, Childhood Autism Rating Scale, CARS, efficacy, acceptability, tolerability
format	article
author	Maneeton N Maneeton B Putthisri S Woottiluk P Narkpongphun A Srisurapanont M
author_facet	Maneeton N Maneeton B Putthisri S Woottiluk P Narkpongphun A Srisurapanont M
author_sort	Maneeton N
title	Risperidone for children and adolescents with autism spectrum disorder: a systematic review
title_short	Risperidone for children and adolescents with autism spectrum disorder: a systematic review
title_full	Risperidone for children and adolescents with autism spectrum disorder: a systematic review
title_fullStr	Risperidone for children and adolescents with autism spectrum disorder: a systematic review
title_full_unstemmed	Risperidone for children and adolescents with autism spectrum disorder: a systematic review
title_sort	risperidone for children and adolescents with autism spectrum disorder: a systematic review
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/0f18bdfe980b4a8395765491e9c5d162
work_keys_str_mv	AT maneetonn risperidoneforchildrenandadolescentswithautismspectrumdisorderasystematicreview AT maneetonb risperidoneforchildrenandadolescentswithautismspectrumdisorderasystematicreview AT putthisris risperidoneforchildrenandadolescentswithautismspectrumdisorderasystematicreview AT woottilukp risperidoneforchildrenandadolescentswithautismspectrumdisorderasystematicreview AT narkpongphuna risperidoneforchildrenandadolescentswithautismspectrumdisorderasystematicreview AT srisurapanontm risperidoneforchildrenandadolescentswithautismspectrumdisorderasystematicreview
_version_	1718401231226929152

Risperidone for children and adolescents with autism spectrum disorder: a systematic review

Ejemplares similares